This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Japanese regulators outline acceptable collaborations among generic drug makers

( February 17, 2025, 09:07 GMT | Official Statement) -- MLex Summary: Japan's healthcare and competition regulators today jointly published examples of acceptable collaborations among generic drug makers under the Antimonopoly Act, addressing the recent public concern over shortages of certain generic drugs. The Japan Fair Trade Commission and the health ministry said that having five suppliers for certain drug components might be ideal and emphasized the need for more consolidations and collaborations. They highlighted lawful practices from perspectives such as merger reviews, information exchange and joint procurements and productions to alleviate some companies' concerns about antitrust violations. The statements, in Japanese, are attached. ...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Documents

Related Sections